Immune checkpoint landscape of human atherosclerosis and influence of cardiometabolic factors.

Autor: Barcia Durán JG; NYU Cardiovascular Research Center, Division of Cardiology, Department of Medicine, New York University Grossman School of Medicine, New York, NY, USA., Das D; NYU Cardiovascular Research Center, Division of Cardiology, Department of Medicine, New York University Grossman School of Medicine, New York, NY, USA., Gildea M; NYU Cardiovascular Research Center, Division of Cardiology, Department of Medicine, New York University Grossman School of Medicine, New York, NY, USA., Amadori L; NYU Cardiovascular Research Center, Division of Cardiology, Department of Medicine, New York University Grossman School of Medicine, New York, NY, USA., Gourvest M; NYU Cardiovascular Research Center, Division of Cardiology, Department of Medicine, New York University Grossman School of Medicine, New York, NY, USA., Kaur R; NYU Cardiovascular Research Center, Division of Cardiology, Department of Medicine, New York University Grossman School of Medicine, New York, NY, USA., Eberhardt N; NYU Cardiovascular Research Center, Division of Cardiology, Department of Medicine, New York University Grossman School of Medicine, New York, NY, USA., Smyrnis P; NYU Cardiovascular Research Center, Division of Cardiology, Department of Medicine, New York University Grossman School of Medicine, New York, NY, USA., Cilhoroz B; NYU Cardiovascular Research Center, Division of Cardiology, Department of Medicine, New York University Grossman School of Medicine, New York, NY, USA., Sajja S; NYU Cardiovascular Research Center, Division of Cardiology, Department of Medicine, New York University Grossman School of Medicine, New York, NY, USA., Rahman K; Division of Cardiology, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA., Fernandez DM; Division of Cardiology, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA., Faries P; Department of Surgery, Vascular Division, Icahn School of Medicine at Mount Sinai, New York, NY, USA., Narula N; Department of Pathology, New York University Grossman School of Medicine, New York University Langone Health, New York, NY, USA., Vanguri R; Division of Precision Medicine, Department of Medicine, New York University Grossman School of Medicine, New York, NY, USA., Goldberg IJ; Division of Endocrinology, Department of Medicine, New York University Grossman School of Medicine, New York, NY, USA., Fisher EA; NYU Cardiovascular Research Center, Division of Cardiology, Department of Medicine, New York University Grossman School of Medicine, New York, NY, USA.; Department of Cell Biology, New York University Grossman School of Medicine, New York, NY, USA., Berger JS; NYU Cardiovascular Research Center, Division of Cardiology, Department of Medicine, New York University Grossman School of Medicine, New York, NY, USA., Moore KJ; NYU Cardiovascular Research Center, Division of Cardiology, Department of Medicine, New York University Grossman School of Medicine, New York, NY, USA. Kathryn.moore@nyulangone.org.; Department of Cell Biology, New York University Grossman School of Medicine, New York, NY, USA. Kathryn.moore@nyulangone.org., Giannarelli C; NYU Cardiovascular Research Center, Division of Cardiology, Department of Medicine, New York University Grossman School of Medicine, New York, NY, USA. chiara.giannarelli@nyulangone.org.; Department of Pathology, New York University Grossman School of Medicine, New York University Langone Health, New York, NY, USA. chiara.giannarelli@nyulangone.org.
Jazyk: angličtina
Zdroj: Nature cardiovascular research [Nat Cardiovasc Res] 2024 Dec; Vol. 3 (12), pp. 1482-1502. Date of Electronic Publication: 2024 Nov 29.
DOI: 10.1038/s44161-024-00563-4
Abstrakt: Immune checkpoint inhibitor (ICI) therapies can increase the risk of cardiovascular events in survivors of cancer by worsening atherosclerosis. Here we map the expression of immune checkpoints (ICs) within human carotid and coronary atherosclerotic plaques, revealing a network of immune cell interactions that ICI treatments can unintentionally target in arteries. We identify a population of mature, regulatory CCR7 + FSCN1 + dendritic cells, similar to those described in tumors, as a hub of IC-mediated signaling within plaques. Additionally, we show that type 2 diabetes and lipid-lowering therapies alter immune cell interactions through PD-1, CTLA4, LAG3 and other IC targets in clinical development, impacting plaque inflammation. This comprehensive map of the IC interactome in healthy and cardiometabolic disease states provides a framework for understanding the potential adverse and beneficial impacts of approved and investigational ICIs on atherosclerosis, setting the stage for designing ICI strategies that minimize cardiovascular disease risk in cancer survivors.
Competing Interests: Competing interests: The authors declare no competing interests.
(© 2024. The Author(s).)
Databáze: MEDLINE
Externí odkaz: